Advertisement
U.S. markets closed

Pulmatrix, Inc. (PULM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
6.04-0.08 (-1.31%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close6.12
Open6.23
Bid5.96 x 100
Ask6.11 x 100
Day's Range5.97 - 6.56
52 Week Range1.55 - 8.44
Volume140,596
Avg. Volume424,054
Market Cap22.06M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-2.64
Earnings DateNov 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Pulmatrix and Cullgen Announce Proposed Merger

    Pulmatrix, Inc. ("Pulmatrix") (Nasdaq: PULM), a clinical-stage biopharmaceutical company, today announced a merger agreement with Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases. Cullgen utilizes its proprietary technology platform, uSMITE™, featuring novel E3 ligands, to build the next generation of target

  • Simply Wall St.

    Pulmatrix Third Quarter 2024 Earnings: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)

    Pulmatrix ( NASDAQ:PULM ) Third Quarter 2024 Results Key Financial Results Revenue: US$366.0k (down 79% from 3Q 2023...